FI914928A - HYDROXIMETHYL (METHYLENCYCLOPENTYL) PURINER OCH -PYRIMIDINER. - Google Patents

HYDROXIMETHYL (METHYLENCYCLOPENTYL) PURINER OCH -PYRIMIDINER. Download PDF

Info

Publication number
FI914928A
FI914928A FI914928A FI914928A FI914928A FI 914928 A FI914928 A FI 914928A FI 914928 A FI914928 A FI 914928A FI 914928 A FI914928 A FI 914928A FI 914928 A FI914928 A FI 914928A
Authority
FI
Finland
Prior art keywords
puriner
methylencyclopentyl
pyrimidiner
hydroximethyl
och
Prior art date
Application number
FI914928A
Other languages
Finnish (fi)
Other versions
FI109905B (en
FI914928A0 (en
Inventor
Robert Zahler
William A Slusarchyk
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400159&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI914928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of FI914928A0 publication Critical patent/FI914928A0/en
Publication of FI914928A publication Critical patent/FI914928A/en
Application granted granted Critical
Publication of FI109905B publication Critical patent/FI109905B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Abstract

Antiviral activity is exhibited by compounds having the formula <CHEM> and its pharmaceutically acceptable salts. v
FI914928A 1990-10-18 1991-10-18 Process for the preparation of antiviral hydroxymethyl (methylene cyclopentyl) purines and pyrimidines FI109905B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59956890A 1990-10-18 1990-10-18
US59956890 1990-10-18

Publications (3)

Publication Number Publication Date
FI914928A0 FI914928A0 (en) 1991-10-18
FI914928A true FI914928A (en) 1992-04-19
FI109905B FI109905B (en) 2002-10-31

Family

ID=24400159

Family Applications (1)

Application Number Title Priority Date Filing Date
FI914928A FI109905B (en) 1990-10-18 1991-10-18 Process for the preparation of antiviral hydroxymethyl (methylene cyclopentyl) purines and pyrimidines

Country Status (28)

Country Link
US (1) US5206244A (en)
EP (1) EP0481754B1 (en)
JP (1) JP2994117B2 (en)
KR (1) KR0160523B1 (en)
CN (1) CN1030916C (en)
AT (1) ATE157095T1 (en)
AU (1) AU634423B2 (en)
BR (1) BR1100846A (en)
CA (1) CA2053339C (en)
CY (2) CY2063B1 (en)
DE (3) DE69127336T2 (en)
DK (1) DK0481754T3 (en)
ES (1) ES2104673T3 (en)
FI (1) FI109905B (en)
GR (1) GR3025395T3 (en)
HK (1) HK1001343A1 (en)
HU (1) HU213207B (en)
IE (1) IE913451A1 (en)
IL (1) IL99755A (en)
LU (1) LU91275I2 (en)
NL (1) NL300241I1 (en)
NO (2) NO179906C (en)
NZ (1) NZ240053A (en)
PL (1) PL169403B1 (en)
PT (1) PT99281B (en)
RU (1) RU2037496C1 (en)
SG (1) SG70958A1 (en)
ZA (1) ZA917894B (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0630897A3 (en) 1993-06-25 1995-03-01 Bristol Myers Squibb Co 3-Hydroxy-4-hydroxymethyl-2-methylene-cyclopentyl purines and pyrimidines.
WO1996001834A1 (en) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-deoxy-2'-(substituted or unsubstituted methylidene)-4'-thionucleoside
AU4303996A (en) * 1994-12-19 1996-07-10 Novartis Ag 6'-substituted carbocyclic nucleosides
GB9520363D0 (en) * 1995-10-05 1995-12-06 Chiroscience Ltd Compounds
AU4090697A (en) * 1996-09-03 1998-03-26 Bristol-Myers Squibb Company Improved process for preparing the antiviral agent {1s-(1alpha, 3alpha, 4beta)}-2-amino-1,9-dihydro-9-{4-hydroxy-3-(hydroxymethyl)-2 -methylenecyclopentyl}-6h-purin-6-one
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
SG132498A1 (en) * 1998-08-10 2007-06-28 Idenix Pharmaceuticals Inc Beta-l-2æ-deoxy-nucleosides for the treatment of hepatitis b
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
EA006181B1 (en) 2000-02-29 2005-10-27 Бристоль-Мейерз Сквибб Компани Based on entecavir pharmaceutical composition and method of preparing thereof
CN102772413A (en) * 2000-02-29 2012-11-14 布里斯托尔-迈尔斯斯奎布公司 Low dose entecavir formulation and use
US20020056123A1 (en) * 2000-03-09 2002-05-09 Gad Liwerant Sharing a streaming video
MY131488A (en) * 2002-04-08 2007-08-30 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
US7153691B2 (en) * 2002-11-13 2006-12-26 G6 Science Corp. Method of identifying and assessing DNA euchromatin in biological cells for detecting disease, monitoring wellness, assessing bio-activity, and screening pharmacological agents
PL397715A1 (en) * 2002-12-11 2012-03-26 Bristol-Myers Squibb Company Cyclopentadiene derivative and the process for the preparation thereof
US7511139B2 (en) * 2004-06-04 2009-03-31 Bristol-Myers Squibb Company Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
TW200540175A (en) * 2004-06-04 2005-12-16 Bristol Myers Squibb Co Process for the preparation of entecavir and novel intermediates thereof via carbon-silicon oxidation
CN100379736C (en) * 2005-05-13 2008-04-09 上海仲夏化学有限公司 Preparation process of entecavir
CN1699366A (en) * 2005-06-03 2005-11-23 北京市典范科技有限责任公司 Purine derivatives
CN1907987B (en) * 2005-08-03 2010-05-05 江苏正大天晴药业股份有限公司 Entecavir acid addition salt, preparation method and use thereof
US20070060599A1 (en) * 2005-09-09 2007-03-15 Dimarco John D Crystalline forms of [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one
CN101016299B (en) * 2006-02-09 2010-05-12 北京典范科技有限责任公司 Process for preparing purine derivatives
CN101130542B (en) * 2006-08-24 2010-08-04 江苏正大天晴药业股份有限公司 Synthesis method of antiviral nucleoside analogue
CN101210015B (en) * 2006-12-26 2010-09-22 上海国创医药有限公司 Method for preparing hepatitis B therapeutic medicament entecavir
CN101245068A (en) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 Crystallization type entecavir, method of producing the same, pharmaceutical composition and uses thereof
CN101074217B (en) * 2007-04-04 2010-11-24 北京精华***医药科技有限公司 Method for obtaining endicawil critical intermediate by chromatogram separation
PT2514750E (en) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
US20090076038A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched entecavir
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CN102325783A (en) 2008-12-23 2012-01-18 法莫赛特股份有限公司 Synthesis of purine nucleosides
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
KR101150254B1 (en) 2008-12-26 2012-06-12 한미사이언스 주식회사 Process for preparing entecavir and intermediates used therein
CN101531660B (en) * 2009-04-14 2012-07-04 安徽贝克联合制药有限公司 Industrialization production process of entecavir-monohydrate
KR101301200B1 (en) 2009-10-12 2013-09-06 한미사이언스 주식회사 Novel method for preparing entecavir and intermediate used therein
US9700560B2 (en) * 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN101759698B (en) * 2009-12-15 2012-01-18 上海医药集团股份有限公司 Method for preparing entecavir
US8481728B2 (en) * 2010-02-16 2013-07-09 Scinopharm Taiwan, Ltd. Process for preparing entecavir and its intermediates
SI3290428T1 (en) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
CA2705953C (en) * 2010-05-31 2018-05-01 Alphora Research Inc. Carbanucleoside synthesis and intermediate compounds useful therein
EP2474548A1 (en) 2010-12-23 2012-07-11 Esteve Química, S.A. Preparation process of an antiviral drug and intermediates thereof
EP2508172A1 (en) 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
CN102491960A (en) * 2011-11-16 2012-06-13 福建广生堂药业股份有限公司 Intermediate compound for synthesis of entecavir, and preparation method and application of intermediate compound
EP2597096A1 (en) 2011-11-24 2013-05-29 Esteve Química, S.A. Process for preparing entecavir and intermediates thereof
CN103304375B (en) * 2012-03-12 2017-04-12 浙江奥翔药业股份有限公司 Synthesis intermediate of Entecavir and preparation method thereof
EP2846788A1 (en) 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
EP2832351A1 (en) 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
WO2015051900A1 (en) 2013-10-08 2015-04-16 Pharmathen S.A. Process for the preparation of entecavir through novel intermediates
KR101640504B1 (en) * 2015-04-15 2016-07-18 동방에프티엘(주) Novel process of Entecavir monohydrate
KR101640503B1 (en) * 2015-04-15 2016-07-18 동방에프티엘(주) Improved process for the preparation of entecavir Monohydrate
JP6912100B2 (en) * 2016-11-16 2021-07-28 国立研究開発法人国立国際医療研究センター Nucleoside derivative with physiological activity such as antiviral activity
CN108203435B (en) * 2016-12-16 2020-09-04 正大天晴药业集团股份有限公司 Preparation method of entecavir by using Boc protecting group
CN106749251A (en) * 2017-01-17 2017-05-31 博瑞生物医药泰兴市有限公司 A kind of synthesis of entecavir midbodies and method of purification
KR102197257B1 (en) * 2017-10-19 2020-12-31 단국대학교 천안캠퍼스 산학협력단 Stabilizing composition for aqueous suspension of entecavir fatty acid esters analogs
CN109956975B (en) * 2017-12-22 2020-11-06 浙江柏拉阿图医药科技有限公司 Liver delivery entecavir prodrug nucleoside cyclic phosphate ester compound and application thereof
EP3894395A2 (en) * 2018-12-12 2021-10-20 Janssen BioPharma, Inc. Cyclopentyl nucleoside analogs as anti-virals
CN113024574B (en) * 2019-12-25 2024-03-29 南通诺泰生物医药技术有限公司 Preparation method of oxadicyclohexane compound
CN111732589B (en) * 2020-06-08 2021-07-30 王乔 Improved entecavir intermediate synthesis process and improved entecavir synthesis process
CN112625041A (en) * 2020-12-25 2021-04-09 常州博海威医药科技股份有限公司 Novel preparation method and intermediate of entecavir
CN115433188A (en) * 2022-09-29 2022-12-06 苏州东瑞制药有限公司 Preparation method of entecavir

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (en) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US5063233A (en) * 1986-11-14 1991-11-05 Ciba-Geigy Corporation N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists
EP0310673B1 (en) * 1987-03-19 1995-07-05 Yamasa Shoyu Kabushiki Kaisha 2'-alkylidenepyrimidine nucleoside derivatives, process for their preparation, and their use
US4997925A (en) * 1987-08-26 1991-03-05 Merrell Dow Pharmaceuticals Inc. 5'-deoxy-5',5'-dihalo adenosines and purine analogues
NZ225906A (en) * 1987-08-26 1990-10-26 Merrell Dow Pharma Aristeromycin/adenosine derivatives and pharmaceutical compositions
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
ATE154359T1 (en) * 1988-08-25 1997-06-15 Yoshitomi Pharmaceutical 2'-METHYLIDENEPYRIMIDINE NUCLEOSIDE COMPOUNDS, THEIR USE AND METHOD FOR THEIR PRODUCTION
HU204843B (en) * 1988-09-27 1992-02-28 Merrell Dow Pharma Process for producing 2'-halogen-methylidene adenosine derivatives and pharmaceutical compositions comprising same
GB8916478D0 (en) * 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5064961A (en) * 1989-12-18 1991-11-12 E. R. Squibb & Sons, Inc. Process for preparing an optically active cyclobutane nucleoside
US5057630A (en) * 1990-04-06 1991-10-15 Glaxo Inc. Synthesis of cyclopentene derivatives

Also Published As

Publication number Publication date
JPH04282373A (en) 1992-10-07
HUT59109A (en) 1992-04-28
EP0481754A3 (en) 1992-09-16
NO2006018I2 (en) 2008-10-20
BR1100846A (en) 2000-04-18
DE69127336T2 (en) 1998-01-02
CA2053339C (en) 2001-05-29
ZA917894B (en) 1993-03-31
IL99755A (en) 1996-08-04
FI109905B (en) 2002-10-31
SG70958A1 (en) 2000-03-21
EP0481754A2 (en) 1992-04-22
KR0160523B1 (en) 1998-12-01
DE122006000069I1 (en) 2007-05-24
CN1030916C (en) 1996-02-07
US5206244A (en) 1993-04-27
FI914928A0 (en) 1991-10-18
PL169403B1 (en) 1996-07-31
NO179906C (en) 1997-01-08
LU91275I2 (en) 2007-06-16
ES2104673T3 (en) 1997-10-16
EP0481754B1 (en) 1997-08-20
HU913283D0 (en) 1992-01-28
DK0481754T3 (en) 1997-09-15
NZ240053A (en) 1993-05-26
NL300241I1 (en) 2006-12-01
DE69127336D1 (en) 1997-09-25
DE122006000069I2 (en) 2012-04-19
JP2994117B2 (en) 1999-12-27
NO179906B (en) 1996-09-30
PT99281B (en) 1999-04-30
PT99281A (en) 1992-08-31
NO2006018I1 (en) 2006-12-27
PL292101A1 (en) 1992-08-10
IE913451A1 (en) 1992-04-22
ATE157095T1 (en) 1997-09-15
NO914089L (en) 1992-04-21
RU2037496C1 (en) 1995-06-19
IL99755A0 (en) 1992-08-18
AU8559891A (en) 1992-04-30
CY2006008I1 (en) 2009-11-04
CA2053339A1 (en) 1992-04-19
HK1001343A1 (en) 1998-06-12
GR3025395T3 (en) 1998-02-27
CY2063B1 (en) 1998-06-12
AU634423B2 (en) 1993-02-18
CN1061972A (en) 1992-06-17
HU213207B (en) 1997-03-28
KR920008043A (en) 1992-05-27
CY2006008I2 (en) 2016-10-05
NO914089D0 (en) 1991-10-17

Similar Documents

Publication Publication Date Title
FI914928A (en) HYDROXIMETHYL (METHYLENCYCLOPENTYL) PURINER OCH -PYRIMIDINER.
ES2056096T3 (en) PURINYL-CYCLLOBUTANES.
SE9100920D0 (en) NEW ACTIVE COMPOUNDS
FI915194A0 (en) HETEROAROYLDERIVAT AV MONOCYCLIS B-LACTAMANT BIOOTICS.
ATE156486T1 (en) FUNGICIDAL 3,4-DIARYL-(5H)-FURAN-2-ONE DERIVATIVES
ES2106058T3 (en) BENZAMIDE DERIVATIVES.
ES2093051T3 (en) PURINIL- AND PIRIMIDIL-TETRAHIDROFURANOS.
ATE159253T1 (en) 2-THIAZOLYLPYRROLEAKRYLATES WITH FUNGICIDAL EFFECT

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate application filed

Spc suppl protection certif: L20060019

PC Transfer of assignment of patent

Owner name: E.R. SQUIBB & SONS, L.L.C.

Free format text: E.R. SQUIBB & SONS, L.L.C.

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 237

Extension date: 20161018

MA Patent expired
SPCE Application for extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: L20060019

SPCP Extension of a supplementary protection certificate [pediatric extension]

Spc suppl protection certif: 237

Extension date: 20170418